Pair page
Enclomiphene Citrate with Zuclomiphene
Mechanism-tag overlap and published literature for Enclomiphene Citrate and Zuclomiphene, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
selective-estrogen-receptor-modulatorserm
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying Enclomiphene Citrate and Zuclomiphene have published these mechanism-level observations. Not a co-administration recommendation.
Co-existence with enclomiphene defines racemic clomiphene (Clomid). The mechanistic argument for separating the two isomers in male hypogonadism therapy is precisely that zuclomiphene's chronic accumulation reverses enclomiphene's testosterone-restoring effect. The two are not a deliberate stack — they are an unintentional pairing inherent to using the racemic drug.
Quick facts
Enclomiphene Citrate
Zuclomiphene
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2016 | Enclomiphene Citrate | Kim ED, McCullough A, Kaminetsky J. Oral enclomiphene citrate raises testosterone and preserves sperm counts in obese hypogonadal men, unlike topical testosterone: restoration instead of replacement. BJU Int. 2016;117(4):677-685. PMID: 26496621. (Pivotal Phase 3 RCT data.) PMID 26496621 | human trial, Phase 3 |
| — | Enclomiphene Citrate | ClinicalTrials.gov NCT01406964, NCT01403038 — Repros Phase 3 ZA-203 / ZA-204 trials. | human trial, Phase 3 |
| 2015 | Enclomiphene Citrate | Helo S, Ellen J, Mechlin C, Feustel P, Grossman M, Ditkoff E, McCullough A. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med. 2015;12(8):1761-1769. | human trial |
| 2019 | Enclomiphene Citrate | Earl JA, Kim ED. Enclomiphene citrate: A treatment that maintains fertility in men with secondary hypogonadism. Expert Rev Endocrinol Metab. 2019;14(3):157-165. (Modern clinical review.) | human study |
| 2018 | Enclomiphene Citrate | Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. | human study |
| 2016 | Enclomiphene Citrate | Pastuszak AW, Wiehle RD, Hsu K, Lipshultz LI. Enclomiphene Citrate for the Treatment of Secondary Male Hypogonadism. Expert Opin Investig Drugs. 2016;25(10):1233-1240. PMC5009465. (Comprehensive clinical review.) | human study |
| 2014 | Enclomiphene Citrate | Wiehle RD, Fontenot GK, Hsu K, Lipshultz L. Oral Enclomiphene Citrate Stimulates the Endogenous Production of Testosterone and Sperm Counts in Men with Low Testosterone: Comparison with Testosterone Gel. J Sex Med. 2014;11(5):1208-1218. | human study |
| 2013 | Enclomiphene Citrate | Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. | human study |
| 2013 | Enclomiphene Citrate | Wiehle RD, Fontenot GK. Oral enclomiphene citrate lowers IGF-1 in men with secondary hypogonadism while raising testosterone: implications for cancer prevention. Cancer Res. 2013;73(8 Supplement):1326. (AACR abstract.) | human study |
| 2009 | Enclomiphene Citrate | Hill S, Arutchelvam V, Quinton R. Enclomiphene, an estrogen receptor antagonist for the treatment of testosterone deficiency in men. IDrugs. 2009;12(2):109-119. (Foundational enclomiphene clinical pharmacology paper.) | human study |
| 2003 | Enclomiphene Citrate | Guay AT, Jacobson J, Perez JB, Hodge MB, Velasquez E. Clomiphene increases free testosterone levels in men with both secondary hypogonadism and erectile dysfunction: who does and does not benefit? Int J Impot Res. 2003;15(3):156-165. | human study |
| 2013 | Enclomiphene Citrate | Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU Int. 2013;112(8):1188-1200. PMC4155868. (PK/PD study; 48 men; 6 weeks.) | pharmacology |
| 2020 | Zuclomiphene | Veru Inc. Press release: "Veru Announces Positive Top-Line Interim Data from Phase 2 Clinical Trial of Zuclomiphene to Treat Hot Flashes in Men with Prostate Cancer on Androgen Deprivation Therapy." January 13, 2020. (Top-line interim Phase 2 efficacy disclosure for VERU-944.) | human trial, Phase 2 |
| 2019 | Zuclomiphene | Getzenberg RH, Rodriguez D, Hancock ML, Fisch H, Steiner MS. A phase II, dose finding, placebo-controlled, study of zuclomiphene citrate to ameliorate the frequency and severity of hot flashes caused by androgen deprivation in men with advanced prostate cancer. J Clin Oncol. 201… | human trial, Phase 2 |
| 2014 | Zuclomiphene | Wiehle RD, Fontenot GK, Wike J, Hsu K, Nydell J, Lipshultz L; ZA-203 Clinical Study Group. Enclomiphene citrate stimulates testosterone production while preventing oligospermia: a randomized phase II clinical trial comparing topical testosterone. Fertil Steril. 2014;102(3):720-7… PMID 24833744 | human trial, Phase 2 |
| 2025 | Zuclomiphene | Joshua AM. A Review of Hot Flash Management in Patients With Prostate Cancer. J Clin Endocrinol Metab. 2025;110(9):2509-2519. PMID: 40397707. (Contemporary review of vasomotor-symptom management in ADT, including zuclomiphene and NK3R antagonists.) PMID 40397707 | human study |
| 2018 | Zuclomiphene | Bhasin S, Brito JP, Cunningham GR, Hayes FJ, Hodis HN, Matsumoto AM, Snyder PJ, Swerdloff RS, Wu FC, Yialamas MA. Testosterone Therapy in Men With Hypogonadism: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab. 2018;103(5):1715-1744. PMID: 29562364. (Con… PMID 29562364 | human study |
| 2013 | Zuclomiphene | Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. PMID: 23411589. PMID 23411589 | human study |
| 2009 | Zuclomiphene | Ghosh BR, Speroff L, Ke RW, Nelson DM, Soules MR. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol. 2009;49(6):674-684. PMID: 19033451. PMID 19033451 | human study |
| — | Zuclomiphene | Hill SE, Bell M, Fontenot G, Wiehle RD. The Isomers of Clomiphene Citrate have Dissimilar Dispositions Once Ingested: Results of a Mouse ADME Study. (Mouse radiolabeled distribution and elimination study confirming divergent isomer pharmacokinetics.) | preclinical, in vivo |
| — | Zuclomiphene | StatPearls. Clomiphene. NCBI Bookshelf NBK559292. (Reference drug monograph; confirms zuclomiphene's months-long terminal half-life in healthy volunteers.) | pharmacology |
| 1996 | Zuclomiphene | Adashi EY. Clomiphene citrate-initiated ovulation: a clinical update. Semin Reprod Endocrinol. 1996;14(3):255-263. (Historical pharmacology review of racemic clomiphene establishing isomer composition.) | review |
| 2026 | Zuclomiphene | WADA. The 2026 Prohibited List. World Anti-Doping Agency. wada-ama.org. (Class S4: Hormone and Metabolic Modulators, including SERMs and clomiphene class.) | regulatory / registry |
| 2019 | Zuclomiphene | Miller GD, Moore C, Nair V, Hill B, Willick SE, Rogol AD, Eichner D. Hypothalamic-Pituitary-Testicular Axis Effects and Urinary Detection Following Clomiphene Administration in Males. J Clin Endocrinol Metab. 2019;104(3):906-914. PMID: 30649263. (The controlled male PK/detection… PMID 30649263 | regulatory / registry |
Related pair pages
More research context
Frequently asked
Have Enclomiphene Citrate and Zuclomiphene been studied together?
Researchers have published mechanistic-level co-administration discussion of Enclomiphene Citrate and Zuclomiphene. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do Enclomiphene Citrate and Zuclomiphene share?
Enclomiphene Citrate and Zuclomiphene share these mechanism tags on their Kalios profiles: selective-estrogen-receptor-modulator, serm. Tags are descriptive and verbatim from each compound profile — not an inference of combined effect.
What is the FDA status of Enclomiphene Citrate and Zuclomiphene?
Enclomiphene Citrate: CRL Dec 2015; not approved. Zuclomiphene: Not approved (standalone). FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on Enclomiphene Citrate and Zuclomiphene?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the Enclomiphene Citrate profile and the Zuclomiphene profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026